AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9578010 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TGB (not attaining monotherapy)
Number of subjects: 123
Study 9578010 — intervention group
Group type: COMPARATOR
Intervention: Patients not attaining TGB monotherapy
Number of subjects: 123
Study 7636894 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg and 10 mg)
Number of subjects: 20
Study 7636894 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg or 50 mg)
Number of subjects: 20
Study 7636894 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 20
Study 7636894 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 20
Study 7636894 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Amlodipine and Hydrochlorothiazide
Number of subjects: 20
Study 2526172 — intervention group
Group type: EXPERIMENTAL
Intervention: Raclopride 0.1 to 16 mg
Number of subjects: 8
Study 900460 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane 1/2 MAC for 1/2 hour (dosage=1/4 MAC hour)
Number of subjects: 17
Study 900460 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane 1/2 MAC for 1 MAC hour (dosage=1 MAC hour)
Number of subjects: 17
Study 900460 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane 1/2 MAC for 2 MAC hours (dosage=2 MAC hours)
Number of subjects: 17
Study 900460 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving halothane
Number of subjects: 17
Study 31541606 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual home care (UHC) plus a 30‐day nurse practitioner transitional care program
Number of subjects: 495
Study 31541606 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual home care (UHC) plus nurse practitioner plus a 60‐day health coach program
Number of subjects: 495
Study 31541606 — intervention group
Group type: COMPARATOR
Intervention: Usual home care (UHC)
Number of subjects: 495
Study 30542961 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting style (especially monitoring)
Number of subjects: 6391
Study 30542961 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional alcohol use by parents
Number of subjects: 6391
Study 30542961 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal episodes of drunkenness
Number of subjects: 6391
Study 27476828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intermediate cervical block
Number of subjects: 86
Study 27476828 — intervention group
Group type: COMPARATOR
Intervention: Superficial cervical block
Number of subjects: 86
Study 26093161 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg bid
Number of subjects: 4221
Study 26093161 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg bid
Number of subjects: 4221
Study 26093161 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4221
Study 23493756 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 15
Study 23493756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21807323 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU/kg/wk Epoetin beta
Number of subjects: 54
Study 21807323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Epoetin beta)
Number of subjects: 54
Study 19958585 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsphere formulation of azithromycin with ethyl cellulose
Number of subjects: 0
Study 16444650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray
Number of subjects: 50
Study 16444650 — intervention group
Group type: COMPARATOR
Intervention: Manual irrigation
Number of subjects: 50
Study 14967278 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Hansatome microkeratome head
Number of subjects: 93
Study 14967278 — intervention group
Group type: COMPARATOR
Intervention: Zero-compression Hansatome microkeratome head
Number of subjects: 93
Study 11777261 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine 5% nail lacquer once weekly for 24 weeks and 200 mg itraconazole once daily for 6 weeks (Group AI‐6)
Number of subjects: 131
Study 11777261 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine 5% nail lacquer once weekly for 24 weeks and 200 mg itraconazole once daily for 12 weeks (Group AI‐12)
Number of subjects: 131
Study 11777261 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole monotherapy for 12 weeks (Group I‐12)
Number of subjects: 131
Study 9510275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheters (PAC) for perioperative monitoring and hemodynamic optimization
Number of subjects: 120
Study 9510275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheters (PAC)
Number of subjects: 120
Study 9510275 — intervention group
Group type: COMPARATOR
Intervention: Control group (intravenous hydration and perioperative monitoring without PACs)
Number of subjects: 120
Study 9510275 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC patients
Number of subjects: 120
Study 9510275 — intervention group
Group type: COMPARATOR
Intervention: PAC patients and control group
Number of subjects: 120
Study 7801337 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment of the overstimulated autonomic nervous system
Number of subjects: 0
Study 3230152 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 16617 administered after food
Number of subjects: 12
Study 3230152 — intervention group
Group type: COMPARATOR
Intervention: CGS 16617 administered in fasted state
Number of subjects: 12
Study 30782930 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker
Number of subjects: 150
Study 30782930 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor/angiotensin receptor blocker-based regimen
Number of subjects: 150
Study 29608229 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 29608229 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 Hz stimulation
Number of subjects: 24
Study 29608229 — intervention group
Group type: EXPERIMENTAL
Intervention: 3030 Hz stimulation
Number of subjects: 24
Study 29608229 — intervention group
Group type: EXPERIMENTAL
Intervention: 5882 Hz stimulation
Number of subjects: 24
Study 27215274 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (A. paniculata) 170 mg dried extract tablet b.i.d. p.o.
Number of subjects: 22
Study 27215274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 24977996 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine (L)
Number of subjects: 90
Study 24977996 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 90
Study 24977996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 21128991 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC/ZDV (150 mg/300 mg) followed by BILR 355/r (150 mg/100 mg)
Number of subjects: 51
Study 21128991 — intervention group
Group type: COMPARATOR
Intervention: BILR 355/r (150 mg/100 mg)
Number of subjects: 51
Study 20854164 — intervention group
Group type: EXPERIMENTAL
Intervention: NVC intervention program (n = 39)
Number of subjects: 106
Study 20854164 — intervention group
Group type: COMPARATOR
Intervention: Original program (n = 67)
Number of subjects: 106
Study 17925412 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT with CPS (simulation-trained group)
Number of subjects: 62
Study 17925412 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (traditionally trained group)
Number of subjects: 62
Study 15660030 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 600
Study 15660030 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 600
Study 11803309 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC, approximately 10 microg/kg)
Number of subjects: 22
Study 11803309 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone (0.2 mg/kg)
Number of subjects: 22
Study 11803309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9972768 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Reinforced Laryngeal Mask Airway (FRLMA)
Number of subjects: 114
Study 9972768 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ET) extubated awake
Number of subjects: 114
Study 9972768 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ET) extubated deeply anesthetized
Number of subjects: 114
Study 7576389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1.3% soluble pyrophosphate and 1.5% PVM/MA copolymer in a 0.243% sodium fluoride/silica base
Number of subjects: 0
Study 7576389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 2% PVM/MA copolymer in a 0.243% sodium fluoride/silica base
Number of subjects: 0
Study 7576389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 0.75% zinc citrate in a 1.14% sodium monofluorophosphate/silica base
Number of subjects: 0
Study 7576389 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (0.243% sodium fluoride/silica)
Number of subjects: 0
Study 2175776 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction using all teaching variables prescribed in the Tennyson‐Cocchiarella model for concept attainment (Group 3)
Number of subjects: 0
Study 2175776 — intervention group
Group type: COMPARATOR
Intervention: Other two groups (Control groups)
Number of subjects: 0
Study 398127 — intervention group
Group type: EXPERIMENTAL
Intervention: dezocine 10 mg
Number of subjects: 61
Study 398127 — intervention group
Group type: EXPERIMENTAL
Intervention: dezocine 15 mg
Number of subjects: 61
Study 398127 — intervention group
Group type: COMPARATOR
Intervention: meperidine 100 mg
Number of subjects: 61
Study 398127 — intervention group
Group type: EXPERIMENTAL
Intervention: dezocine (both doses)
Number of subjects: 61
Study 398127 — intervention group
Group type: COMPARATOR
Intervention: dezocine and meperidine
Number of subjects: 61
Study 6641092 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine (40 mg three times a day)
Number of subjects: 0
Study 6641092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31118201 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (more frequent and lower doses)
Number of subjects: 4
Study 31118201 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents (lower doses)
Number of subjects: 4
Study 31118201 — intervention group
Group type: EXPERIMENTAL
Intervention: Model predictions after 12 weeks of treatment
Number of subjects: 4
Study 31118201 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative regimens suggested by model simulations
Number of subjects: 4
Study 30261238 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter heart valve (THV) system
Number of subjects: 941
Study 27909035 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Blockade (TEB)
Number of subjects: 0
Study 27909035 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral Continuous Paravertebral Blockade (PVB)
Number of subjects: 0
Study 27909035 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 24987942 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid in each capsule), daily for 4 months
Number of subjects: 40
Study 24987942 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Number of subjects: 40
Study 24987942 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 22074027 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimaxillary flask (BMF) with silicone wall
Number of subjects: 40
Study 22074027 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimaxillary flask (BMF) with stone wall
Number of subjects: 40
Study 22074027 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomaxillary flask with stone wall
Number of subjects: 40
Study 22074027 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimaxillary flask (BMF) with acrylic resin retentions and silicone
Number of subjects: 40
Study 22074027 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 19021601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg as needed or once daily for 9 weeks
Number of subjects: 1238
Study 19021601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1238
Study 19021601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg as needed
Number of subjects: 1238
Study 17458576 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryostimulation at -120 to -140 degrees C during a ten-day training cycle
Number of subjects: 0
Study 17458576 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryostimulation during training
Number of subjects: 0
Study 17458576 — intervention group
Group type: COMPARATOR
Intervention: Control training without cryostimulation
Number of subjects: 0
Study 15913621 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion (1000 mL of warmed sterile saline solution)
Number of subjects: 438
Study 15913621 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional treatment only)
Number of subjects: 438
Study 12459525 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium gluconate ointment dosed at 8%
Number of subjects: 129
Study 12459525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 10604553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg, once daily (n = 97)
Number of subjects: 288
Study 10604553 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levocabastine 200 microg, twice daily (n = 96)
Number of subjects: 288
Study 10604553 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (n = 95)
Number of subjects: 288
Study 7722163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg administered by metered-dose inhaler, twice daily)
Number of subjects: 112
Study 7722163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 1904028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 721
Study 1904028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 721
Study 6118717 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 76
Study 6118717 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 76
Study 31126174 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education for four sessions lasting 35–40 minutes with a booster phone call
Number of subjects: 110
Study 31126174 — intervention group
Group type: COMPARATOR
Intervention: Routine GDM education program
Number of subjects: 110
Study 27836885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day
Number of subjects: 171
Study 27836885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 27836885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 171
Study 25475772 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% bioadhesive chlorhexidine gel
Number of subjects: 160
Study 25475772 — intervention group
Group type: COMPARATOR
Intervention: bioadhesive placebo
Number of subjects: 160
Study 23663078 — intervention group
Group type: EXPERIMENTAL
Intervention: Viniyoga intervention (yoga practice 5 times per week for 6 months)
Number of subjects: 32
Study 23663078 — intervention group
Group type: EXPERIMENTAL
Intervention: Viniyoga intervention (yoga classes)
Number of subjects: 32
Study 23663078 — intervention group
Group type: EXPERIMENTAL
Intervention: Viniyoga intervention (home-based yoga sessions)
Number of subjects: 32
Study 23663078 — intervention group
Group type: EXPERIMENTAL
Intervention: Viniyoga intervention
Number of subjects: 32
Study 21827654 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered method for early identification of social-emotional and behavioral problems
Number of subjects: 3500
Study 21827654 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control condition)
Number of subjects: 3500
Study 19473538 — intervention group
Group type: EXPERIMENTAL
Intervention: External shock wave therapy (ESWT) combined with standard care
Number of subjects: 30
Study 19473538 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 30
Study 17243107 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component smoking cessation intervention (nurse led behavioral/empowerment counseling, nicotine replacement therapy, community health workers)
Number of subjects: 0
Study 17243107 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 0
Study 15502720 — intervention group
Group type: EXPERIMENTAL
Intervention: C2-monitored regimen (n=50)
Number of subjects: 100
Study 15502720 — intervention group
Group type: COMPARATOR
Intervention: C0-monitored regimen (n=50)
Number of subjects: 100
Study 12029233 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutkow technique (group A)
Number of subjects: 150
Study 12029233 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabucco technique (group B)
Number of subjects: 150
Study 12029233 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein technique (group C)
Number of subjects: 150
Study 10193877 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (0.75 pmol x kg(‐1) min(‐1))
Number of subjects: 8
Study 10193877 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 7564097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulosic membranes
Number of subjects: 0
Study 7564097 — intervention group
Group type: COMPARATOR
Intervention: Polyacrylonitrile membranes
Number of subjects: 0
Study 7564097 — intervention group
Group type: COMPARATOR
Intervention: Cuprophane membranes
Number of subjects: 0
Study 7564097 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement activated serum
Number of subjects: 0
Study 7564097 — intervention group
Group type: EXPERIMENTAL
Intervention: hrC5a
Number of subjects: 0
Study 7564097 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal human serum
Number of subjects: 0
Study 2376386 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution (5%) applied topically, 2 drops
Number of subjects: 52
Study 2376386 — intervention group
Group type: COMPARATOR
Intervention: NaCl solution, 2 drops
Number of subjects: 52
Study 7387941 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline episiotomy
Number of subjects: 407
Study 7387941 — intervention group
Group type: COMPARATOR
Intervention: Mediolateral episiotomy
Number of subjects: 407
Study 29859498 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management (SM)
Number of subjects: 126
Study 29859498 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Restructuring (CR)
Number of subjects: 126
Study 26248789 — intervention group
Group type: EXPERIMENTAL
Intervention: KICk-OFF course (5-day structured education course)
Number of subjects: 396
Study 26248789 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 396
Study 25436842 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 99
Study 25436842 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 99
Study 25436842 — intervention group
Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 99
Study 22326237 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine (up to 16 mg/24h)
Number of subjects: 217
Study 20386063 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (music group, n = 20)
Number of subjects: 40
Study 20386063 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study 18316526 — intervention group
Group type: COMPARATOR
Intervention: Maribavir alone (400 mg)
Number of subjects: 20
Study 18316526 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir plus ketoconazole (400 mg)
Number of subjects: 20
Study 16010245 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) administered during donor operation (IV & Portal flush)
Number of subjects: 22
Study 16010245 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no NAC)
Number of subjects: 22
Study 12439090 — intervention group
Group type: EXPERIMENTAL
Intervention: Gymnasts
Number of subjects: 50
Study 12439090 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 50
Study 10826458 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine hydrochloride, 150 mg twice daily
Number of subjects: 353
Study 10826458 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, 15 mg once daily
Number of subjects: 353
Study 10826458 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg once daily
Number of subjects: 353
Study 9055014 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical squaric acid dibutylester (SADBE) applied weekly for 20 weeks after sensitization with 2% SADBE in acetone
Number of subjects: 20
Study 9055014 — intervention group
Group type: COMPARATOR
Intervention: Untreated alopecia sites on the same patient
Number of subjects: 20
Study 9055014 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical squaric acid dibutylester (SADBE)
Number of subjects: 20
Study 1647443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flumazenil (3 mg)
Number of subjects: 10
Study 1647443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (10 mg)
Number of subjects: 10
Study 1647443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6384072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (20.0 +/- 3.13 mg/d)
Number of subjects: 8
Study 6384072 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (125.0 +/- 19.17 mg/d)
Number of subjects: 8
Study 30673710 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer-based intervention (ICBI)
Number of subjects: 272
Study 29119300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 33